conditions for which they were intended, namely, (Special Food Supplement) anemia, allergy, diabetes, impotency, thrombosis, muscular dystrophy, alcoholism, sclerosis of the liver, nervousness, post-operative cancer conditions, and adverse reactions from antibiotics therapy; and, when used in conjunction with vitamin E therapy, phlebitis, heart trouble, nephritis, varicose veins, and chronic conditions of any sort, which are the diseases, symptoms, and conditions for which said drug was held out to the persons present at the aforesaid sales talk; and (Vitamin E Perles) heart trouble, impotency, nervousness, and chronic conditions of any sort; and, when used in conjunction with other vitamin and mineral therapy, phlebitis, varicose veins, nephritis, and diabetes, which are the diseases, symptoms, and conditions for which said drug was held out to the persons present at the aforesaid sales talk.

PLEA: Guilty.

DISPOSITION: 4–6–60. $100 fine, six months jail sentence which was suspended, and probation for 1 year.

6050. Various prescription drugs. (F.D.C. No. 44215. S. Nos. 46–613/4 P, 46–616/8 P, 92–317 P.)

QUANTITY: 5 100-tablet btls. of *Obocell*, 7 100-tablet btls. of *Syndrox Methamphetamine Hydrochloride*, 3 12-tablet btls. of *penicillin G potassium* (200,000 Units), 1 12-tablet btl. of *penicillin G potassium* (50,000 Units), 5 individually cartoned tubes of *No. 66 ointment*, 1 50-tablet btl. of *Equanil*, 1 50-tablet btl. of *Dexamyl*, 1 50-tablet btl. of *Try-Phetamine Compound No. 3 Pink*, 1 12-tablet btl. of *penicillin G* (100,000 units), 3 25-troche btls. of *Ledercillin Troches*, 1 1-oz. tube of *Lederle Aureomycin ointment*, 2 1-oz. tubes of *Ledercillin procaine penicillin G ointment*, 1 100-tablet btl. of *Bellergal*, 1 ¼-lb. btl. of *chloroform*, 1 ¼-pint btl. *nux vomica NF* at Fultondale, Ala., in possession of Sam K. Mickwee, t/a Fultondale Sundry Store.

SHIPPED: Prior to 12–18–59, from outside the State of Alabama.

LIBELED: 2–1–60, N. Dist. Ala.

CHARGE: 502(f)(1)—while held for sale, the labels of the articles failed to bear adequate directions for use, and the articles were not exempt from that requirement by regulations since the articles were prescription drugs in possession of a person who was not regularly and lawfully engaged in the distribution of prescription drugs, or regularly and lawfully engaged in dispensing prescription drugs.

DISPOSITION: 3–7–60. Default—destruction.

6051. Kay-San ointment. (F.D.C. No. 44164. S. Nos. 80–184/6 P.)

QUANTITY: 14 cases, 24 ¾-oz. jars each, and 24 cases, 12 1⅜-oz. jars each, at Detroit, Mich.

SHIPPED: Between 4–15–59 and 10–21–59, from Wilkes-Barre, Pa., by Stenton Laboratories, Inc.

LABEL IN PART: (Ctn. and jar) "Kay-San * * * Active Ingredients Mercury Salicylate ⅓ Gr. to Oz., Acid Salicylic, Resorcin, Coal Tar * * * Stenton Laboratories, Inc., Wilkes-Barre, Pa."

ACCOMPANYING LABELING: Leaflets in carton entitled "Pauling's Special" and "Kay-San" and sets of counter and display posters, consisting of three posters per set, reading in part "Stop That Itch with Kay-San."

LIBELED: 1–5–60, E. Dist. Mich.

CHARGE: 502(a)—when shipped, the labeling of the article contained false and misleading representations that the article was an adequate and effective treatment for eczema, fungus infections, psoriasis, ringworm, and athletes foot; and 502(f)(2)—the labeling of the article failed to bear a warning that its use should be discontinued if undue or unusual irritation of the skin developed and that frequent or prolonged use or application to large areas of the body may cause serious mercury poisoning.

DISPOSITION: 4–8–60. Consent—destruction.

DRUGS ACTIONABLE BECAUSE OF DEVIATION FROM OFFICIAL OR OWN STANDARD

DRUGS FOR HUMAN USE*

6052. Lobie #1 tablets. (F.D.C. No. 43069. S. No. 25–122 P.)

INDICTMENT RETURNED: 9–14–59, S. Dist. Iowa, against Sentral Laboratories, Inc., Des Moines, Iowa, and James H. Roberts, president.

ALLEGED VIOLATION: On 11–25–57, the defendants gave to a firm engaged in the business of shipping drugs in interstate commerce, including *Lobie #1 tablets* supplied by the defendants, an invoice containing a guaranty that the Lobie #1 listed in the invoice was neither adulterated nor misbranded within the meaning of the Federal Food, Drug, and Cosmetic Act.

On 11–25–57, the defendants sold, invoiced, and shipped a quantity of *Lobie #1 tablets*, which were adulterated, to the holder of the guaranty at Council Bluffs, Iowa.

LABEL IN PART: (Drum) "50,000 Lobie # 1 Each tablet contains: dl–Desoxyephedrine Hcl. 4 mg. Thyroid 1 gr. Atropine Sulfate 1/360 gr. Aloin ¼ gr."

CHARGE: 501(c)—the strength of the article differed from that which it purported and was represented to possess, namely, 4 milligrams of dl–desoxyephedrine hydrochloride in each tablet, since each table of the article contained more than 4 milligrams of dl–desoxyephedrine hydrochloride.

PLEA: Guilty.

DISPOSITION: 12–3–59. Fines were assessed in the amount of $2,500 against the corporation and $1,000 against the individual, plus costs.

6053. Procaine hydrochloride injection. (F.D.C. No. 43327. S. Nos. 48–543 P, 48–822 P.)

QUANTITY: 13,045 vials and 840 pkgs., 12 vials each, at San Francisco, Calif., in possession of Allied Biochemical Laboratories.

SHIPPED: Procaine hydrochloride was shipped on 1–29–59, from St. Louis, Mo.

LABEL IN PART: (Vial) "30 cc. Sterile Procaine Hydrochloride Injection USP 1% [or "2%"]."

RESULTS OF INVESTIGATION: The *procaine hydrochloride injection* was manufactured by the dealer from the procaine hydrochloride which was shipped as described above. Examination of the article showed that the pH (acidity) of procaine hydrochloride was less than 3.3, whereas the United States Pharmacopeia requires that the pH of *procaine hydrochloride injection* be between 3.3 and 5.5.

*See also Nos. 6041, 6043, 6045.